Navigation Links
Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Date:1/25/2008

FRAZER, Pa., Jan. 25 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in opioid-tolerant patients with chronic pain. In addition, the FDA notified the Company that it will convene an advisory committee panel on May 6, 2008, to consider this application.

"We are pleased that the FENTORA application remains on schedule with an FDA action date of September 13, 2008," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "FENTORA is the first medication that has been evaluated in controlled clinical trials for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Therefore, it is not surprising that the agency decided to convene a panel to consider data on the use of FENTORA beyond the initial indication for breakthrough pain in cancer patients."

Included in the FENTORA sNDA are data from three randomized, placebo- controlled clinical trials and one long-term open-label safety study; including data from opioid-tolerant patients with chronic low back and neuropathic pain. The sNDA provides an evaluation of the onset of pain relief from 10 minutes to two hours, and has information regarding bioequivalence data for two routes of administration.

In 2006, FENTORA and an accompanying Risk Minimization Action Plan (RiskMAP) were approved by the FDA only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. The company developed and maintains a FENTORA RiskMAP to address the appropriate patient selection, dosing and administration of the medication.

About Cephalon, Inc.

Cephalon, Inc. is an international biop
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. CardioDynamics Provides 2007 Shareholder Meeting Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... 2014 The Asia-Pacific Bio-based Advanced ... the bio-based advanced phase change material market in ... Browse through the TOC of the Asia-Pacific Bio-based ... an idea of the in-depth analysis provided. This ... the Asia-Pacific bio-based advanced phase change material market, ...
(Date:10/18/2014)... 2014 The Asia-Pacific hardware encryption display ... Asia-Pacific with analysis and forecast of revenue. This market ... to reach $51,362.6 million by 2018, at a CAGR ... the TOC of the Asia-Pacific hardware encryption market report, ... This also provides a glimpse of the segmentation of ...
(Date:10/18/2014)... New York, NY (PRWEB) October 18, 2014 ... at a healthy rate in the five years to ... by several federal renewable energy tax credits that encouraged ... states have enacted renewable portfolio standards (RPSs), which require ... a percentage of their total energy portfolio. Increased campaigning ...
(Date:10/18/2014)... 2014 The “Global Diagnostic Electrocardiograph ... by End-user (Hospitals, Home/Ambulatory, Research Center, Physician Office, ... -Global Forecast to 2020” provides a detailed overview ... market trends, and strategies impacting the global diagnostic ... of the revenue and share analysis. , The ...
Breaking Biology Technology:The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 4The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 2Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 3The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 2The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 3The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 4The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 5
... SAN DIEGO, Feb. 26 Ambrx Inc. today ... as Senior Vice President,for Clinical Research and Development., ... spanning nearly two,decades at Procter & Gamble Pharmaceuticals. ... for Discovery, Early Development and Product,Development where he ...
... NATICK, Mass., Feb. 26 Boston Scientific,Corporation (NYSE: ... Ph.D.,will be joining the Company,s Clinical Sciences organization effective,March ... and Associate Chief Medical,Officer, sitting on the Clinical Leadership ... Dr. Donald S. Baim, M.D. In his new role,Dr. ...
... Feb. 26 BioStorage Technologies, Inc.,(BST), announces the ... the company,s European operations in Griesheim, Germany. Hoffer,joins ... in the fields of,clinical pharmacology and toxicology. In ... M. Saponaro, Chief Operating Officer for BST, and ...
Cached Biology Technology:Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development 2Boston Scientific Announces Addition to Clinical Sciences Organization 2Boston Scientific Announces Addition to Clinical Sciences Organization 3Boston Scientific Announces Addition to Clinical Sciences Organization 4BioStorage Technologies Appoints Dr. Wolfgang Hoffer as Managing Director of European Operations 2
(Date:10/14/2014)... ATHENS, Ohio (Oct. 14, 2014)—It,s been millions of years ... but a team led by Ohio University scientists is ... to model airflow through dinosaur snouts. The research has ... not only breathe but to enhance the sense of ... pretty ,nosy, animals," said Ohio University doctoral student Jason ...
(Date:10/14/2014)... A Mount Sinai-led research team has discovered a new kind ... or a cell that lines liver blood vessels, according to ... Reports . The existence of such a cell type contradicts ... the embryo, and may hold clues to origins of, and ... develop from a single cell into a complex being made ...
(Date:10/14/2014)... team of scientists led by researchers at the ... University of Miami Miller School of Medicine (UMMSM) ... pathway underlying bipolar (manic depressive) disorder, a breakthrough ... bipolar affective disorder, as well as depression and ... published online this week in Nature Molecular ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... (April 19, 2010) Virginia Commonwealth University researchers have ... key role in the development of liver cancer. Levels ... than 90 percent of patients with the disease compared ... Virginia Commonwealth University Massey Cancer Center and the VCU ...
... Md. (April 19, 2010) Chesapeake Biological Laboratory Director ... of Maryland Center for Environmental Science with its President,s ... informing policymakers and the public about the environmental impacts ... Dr. Palmer seeks to expand the impact of her ...
... metals or semiconductors to soft organic or biological products. Picture ... Mother Nature. The applications in medicine and manufacturing ... of nanoscience at The Florida State University. How ... chip" that can diagnose illness? That and much more are ...
Cached Biology News:Researchers identify new gene involved in the development of liver cancer 2UMCES ecologist Margaret Palmer recognized for promoting the role of science in public policy 2Bionanotechnology has new face, world-class future at Florida State 2Bionanotechnology has new face, world-class future at Florida State 3
2ndGen Predilute antibody for staining tissue sections. Optimized for use with Zymeds Histostain-PLUS, NBA, HistoST5050, and Cap-Plus IHC Kits.Labeling: ASR...
Sprague Dawley rats, 7-8 weeks of age, mixed gender; collected by exsanguination in Alsever's solution at 1:2 dilution...
... The S.c. EasyComp Transformation Kit ... transformation-competent Saccharomyces cerevisiae cells. Advantages over ... spheroplast formation or LiCl methods include:- Cells ... than 30 minutes - Competent cell preparation ...
Trop-2 Purified Anti-Human clone 162-46, Isotype Mouse IgG 1 , 100 µg Consult technical datasheet for details....
Biology Products: